Tillotts CEO, Thomas A. Tóth von Kiskér, has been featured in an exclusive interview on PharmaBoardroom.com, analysing the company’s achievements over the past years and reflecting on its ambitious plans. Photos © Tillotts Pharma AG
Pharma Boardroom, an online platform aimed at C-level executives, consultants, regulators and vendors working in Healthcare and Life Sciences globally, recently interviewed Tillotts CEO, Thomas A. Tóth von Kiskér. Here, he shared his thoughts about the importance of M&As for mid-sized pharma companies, having a closer look at the challenges that come across when building a strong portfolio and analysing the potential of the latest product acquisition DIFICLIRTM.
“For small- to mid-sized pharma companies, M&As might be a much better way to build a portfolio quickly and with less risk. With the acquisition of assets, generating revenues, at least the product and the competitive landscape are known and above all income is guaranteed from day one. That being said, it is not always easy for smaller companies to build in-house M&A expertise – or maybe they are not that interested in it – but for Tillotts, we have robust M&A capabilities so we are in a strong position.“
Read the full interview here.